Literature DB >> 27143289

Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks.

S Scott Sutton1, James W Hardin, Thomas J Bramley, Anna O D'Souza, Charles L Bennett.   

Abstract

OBJECTIVES: To evaluate the impact of antiretroviral therapy as a single-tablet regimen (STR) and multiple-tablet regimen (MTR) on outcomes in human immunodeficiency virus (HIV)/AIDS patients using electronic health records from the Veterans Healthcare Administration (VHA). STUDY
DESIGN: Retrospective cohort.
METHODS: This study evaluated VHA patients to whom HIV medications were dispensed as STRs or MTRs during the study period (January 1, 2006, to July 30, 2012). Patients were followed from the index date (ie, start of regimen) until treatment discontinuation, end of study period, last date of healthcare-related activity, or death. Differences in outcomes of hospitalization, adherence defined as a medication possession ratio of ≥ 95%, and undetectable viral load were evaluated using a Cox-proportional hazard and logistic model controlling for covariates measured during a 6-month baseline period.
RESULTS: A total of 15,602 patients (6191 STR and 9411 MTR) met all study criteria. The study sample was, on average, aged 52 years with similar CD4 counts (mean ± SD: 432.2 ± 282.8 vs 419.3 ± 280.9; P = .287), but a significantly lower proportion of STR versus MTR patients had an undetectable viral load at baseline (42% vs 46%; P < .001). After controlling for baseline covariates, the STR cohort had twice the odds of being adherent (odds ratio [OR], 1.98; P < .001), 31% had a significantly lower hazard of having a hospitalization (hazard ratio, 0.69; P < .001), and 21% had higher odds of having an undetectable viral load during follow-up (OR, 1.21; P < .001).
CONCLUSIONS: STR is associated with higher adherence rates, decreased hospitalizations, and more patients with an undetectable viral load in VHA patients with HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27143289

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  23 in total

1.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

2.  Antiretroviral Therapy in Children and Adolescents: A Look Into Modern Single Tablet Regimens.

Authors:  Clara Lee; Jenna Sapasap; Joseph LaRochelle; Renata O Smith; Melissa E Badowski
Journal:  J Pediatr Pharmacol Ther       Date:  2021-11-10

Review 3.  Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need.

Authors:  Monique R Bidell; Milena McLaughlin; John Faragon; Caroline Morse; Nimish Patel
Journal:  Infect Dis Ther       Date:  2016-07-06

Review 4.  Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.

Authors:  Thomas Whitfield; Adele Torkington; Clare van Halsema
Journal:  HIV AIDS (Auckl)       Date:  2016-10-14

5.  Health Care Provider Utilization and Cost of an mHealth Intervention in Vulnerable People Living With HIV in Vancouver, Canada: Prospective Study.

Authors:  Amber R Campbell; Karen Kinvig; Hélène Cf Côté; Richard T Lester; Annie Q Qiu; Evelyn J Maan; Ariane Alimenti; Neora Pick; Melanie Cm Murray
Journal:  JMIR Mhealth Uhealth       Date:  2018-07-09       Impact factor: 4.773

6.  HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens.

Authors:  Shashi N Kapadia; Robert R Grant; Susan B German; Baljinder Singh; Amy L Davidow; Shobha Swaminathan; Sally Hodder
Journal:  SAGE Open Med       Date:  2018-12-04

7.  Identifying causes of persistent HIV viremia in adult patients at an academic medical center.

Authors:  Julie Steinbrink; Hannah Imlay; Krishna Rao; James Riddell
Journal:  SAGE Open Med       Date:  2019-05-14

8.  A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV.

Authors:  Patrick G Clay; Wei C Yuet; Christiane H Moecklinghoff; Inge Duchesne; Krzysztof L Tronczyński; Sandip Shah; Dong Shao
Journal:  AIDS Res Ther       Date:  2018-10-30       Impact factor: 2.250

9.  Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.

Authors:  Julián Olalla; Javier Pérez-Stachowski; Begoña Tortajada; Alfonso Del Arco; Efrén Márquez; Javier De la Torre; Miriam Nieto; José María García de Lomas; José Luis Prada; Javier García-Alegría
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-10       Impact factor: 2.483

10.  Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.

Authors:  James A Simon; Andrew M Kaunitz; Robin Kroll; Shelli Graham; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-05       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.